NCT01131169 · OUTCOME

Number of Participants Who Relapse That Are Restored to Remission (CR)

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions · Source last updated 2021-12-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 3 years

What was measured

To compute the current multiple myeloma free survival curve in order to account for patients who relapse and are restored to remission through DLI.

Analysis population: This group consists of participants with residual disease either because they did not reach CR from salvage and transplant conditioning or because they were given this dose at the time of progression

Groups in this outcome

Relapsed Multiple Myeloma

This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Relapsed Multiple Myeloma	18

Reported measurements

Source class 1

Restored to CR, did not develop GVHD

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Relapsed Multiple Myeloma	4	Not reported	Not reported	Not reported	Not reported

Were not restored to CR, did not develop GVHD

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Relapsed Multiple Myeloma	14	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4
title
Restored to CR, did not develop GVHD
measurements
group Id
OG000
value
14
title
Were not restored to CR, did not develop GVHD

denoms

counts
group Id
OG000
value
18
units
Participants

description

To compute the current multiple myeloma free survival curve in order to account for patients who relapse and are restored to remission through DLI.

groups

description
This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma
id
OG000
title
Relapsed Multiple Myeloma

param Type

COUNT_OF_PARTICIPANTS

population Description

This group consists of participants with residual disease either because they did not reach CR from salvage and transplant conditioning or because they were given this dose at the time of progression

reporting Status

POSTED

time Frame

3 years

title

Number of Participants Who Relapse That Are Restored to Remission (CR)

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice